tbuckley/cabot-search huggingface dataset:
Abstract 3713: Chemoprevention of prostate carcinogenesis in TRAMP mice by α-santalol by causing cell cycle arrest and induction of apoptosis.
Authors: Ajay Bommareddy, William Eggelston, Stacy Prelewicz, Andrea Antal, Adam L. VanWert, Hiral Patel, Aleona Chinikaylo, Linda S. Gutierrez, Santha Sreevidya, Chandradhar Dwivedi
Journal: Cancer Research (2013)

Abstract α-santalol, a major component of sandalwood oil inhibits growth of cultured prostate cancer cells in vitro by causing apoptosis. The present study was undertaken to determine the in vivo efficacy of α-santalol using TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice as a model. The i.p administration of α-santalol (50 mg/kg) did not cause any side effects or weight loss throughout the study. Administration of α-santalol (50 mg/kg) showed a trend in decrease in average wet weights of urogenital weights compared to control mice (∼34% decrease in α-santalol group compared to control). Furthermore, the dorsolateral sections of prostate from α-santalol-treated mice exhibited decreased cell proliferation in association with induction of apoptosis. Western blotting analysis of prostate tumor samples from α-santalol-treated group revealed an increase in the expression levels of cleaved PARP, phospho p53 (ser 15), cleaved caspase-3, cyclin B, p21 and a modest reduction in antiapoptotic protein Bcl-xL compared to control samples. In agreement with these results, α-santalol treatment resulted in G2/M cell cycle arrest in cultured prostate cancer cells. In conclusion, the present study indicates that α-santalol administration inhibits the development of prostate cancer in TRAMP mice by decreasing cell proliferation, causing cell cycle arrest, and inducing apoptosis. This study was supported by Wilkes University Type I grant, American Association of Colleges of Pharmacy and by Translational Cancer Research Center funded by South Dakota Governor's Office of Economic Development. Citation Format: Ajay Bommareddy, William Eggelston, Stacy Prelewicz, Andrea Antal, Adam L. VanWert, Hiral Patel, Aleona Chinikaylo, Linda S. Gutierrez, Santha Sreevidya, Chandradhar Dwivedi. Chemoprevention of prostate carcinogenesis in TRAMP mice by α-santalol by causing cell cycle arrest and induction of apoptosis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3713. doi:10.1158/1538-7445.AM2013-3713
AB0982 Comparison of the Performance of the BASRI and Msasss in Patients with Early Inflammatory Back Pain from the DESIR Cohort:
Authors: M. de Hooge, P. Claudepierre, A. Feydy, M. Reijnierse, A. Saraux, M. Dougados, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> For assessing structural damage in AS on spinal X-rays Bath Ankylosing Spondylitis Radiology Index (BASRI) and modified Stoke Ankylosing Spondylitis <i>Spinal</i> Score (mSASSS) scoring systems can be used <h3>Objectives</h3> To present the prevalence of abnormalities based on the BASRI and mSASSS in patients (pts) with recent inflammatory back pain (IBP) and to compare these 2 scores <h3>Methods</h3> Pts aged 18-50 with recent IBP (≥3 months, ≤3 years) from 25 participating centres in France were included in the DESIR (Devenir des Spondylarthropathies Indifferenciées Récentes)-cohort (n=708). Available baseline spinal X-rays (cervical and lumbar) were scored by 2 well-calibrated central readers independently, blinded for clinical data. When readers disagreed, an experienced radiologist served as adjudicator. BASRI and mSASSS were calculated from the mean of the scores of the 2 readers (and adjudicator if applicable). Pts were classified according to the ASAS axial SpondyloArthritis (ASAS axSpA) criteria into pts fulfilling the imaging arm, either fulfilling or not fulfilling the modified New York (mNY) criteria, fulfilling the clinical arm and not fulfilling (no-axSpA pts) the criteria <h3>Results</h3> Pts with complete X-ray data (n=599) were included in these analyses. Overall, 559 pts (93.3%) had no definite abnormalities assessed by mSASSS &lt;2, and 564 (94.2%) by BASRI &lt;2; 93.0% and 93.5% within the ASAS axSpA group (n=431), respectively (see table). A BASRI of ≥2 was scored more frequently in the imaging arm compared to the clinical arm and no-axSpA pts (table). When comparing mSASSS and BASRI readings, using a cut-off of ≥2 (definite abnormalities) for both scoring methods, we found a very high percentage of agreement in all the different patient groups: range 95.4% to 98.2%. Only in few pts syndesmophytes were found (table). More syndesmophytes were present in cervical spine than in lumbar spine. The number of syndesmophytes in cervical vs lumbar spine was 6 vs 3 in the no-axSpA group, 6 vs 1 in the clinical arm, 5 vs 1 in the imaging mNY-group, and 8 vs 1 in the imaging mNY+ group <h3>Conclusions</h3> The agreement between mSASSS and BASRI ≥2 is very high in all groups. Abnormalities typical for AS such as syndesmophytes are generally infrequent in this early cohort, but if observed, syndesmophytes are more frequent in the cervical spine compared to the lumbar spine. An mSASSS and BASRI of ≥2 is more often seen in pts fulfilling the ASAS classification criteria compared to no-SpA pts <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2662
Coronary Artery Fistula
Authors: WONSICK CHOE, ANGELISA M. PALADIN
Journal: Clinical Nuclear Medicine (1997)

A 38-year-old man with a history of cocaine abuse had an evaluation for chest pain. Myocardial infarction was ruled out, and he underwent an exercise thallium myocardial perfusion SPECT study that suggested myocardial ischemia in the left anterior descending (LAD) artery territory. Cardiac catheterization showed a minimal coronary disease but a coronary artery fistula communicating the LAD artery with the main pulmonary artery. Toxic screen for cocaine was negative.
Abstract P1-04-07: The mRNA Expression of DAP1 in Human Breast Cancer: Correlation with Clinicopathological Parameters
Authors: U Wazir, WG Jiang, AK Sharma, K Mokbel
Journal: Cancer Research (2012)

Abstract BACKGROUND: This pilot study is the first to focus on the potential role for death-associated protein 1 (DAP1) in human breast cancer. MATERIAL AND METHODS: mRNA expression of DAP1 in breast cancer tissues (n = 127) and normal background tissues (n = 33) were determined using quantitative polymerase chain reaction (qPCR) and correlated with clinicopathological data accumulated over a 10-year follow-up period. Furthermore the effects of DAP1 knockout in breast cancer cell lines were investigated. RESULTS: The expression of DAP1 mRNA was demonstrated to decrease with increasing Nottingham Prognostic Index (NPI2 vs. NPI3, p = 0.0026), and TNM stage (TNM1 vs. 4, p = 0.0039). Lower DAP1 expression levels were significantly associated with local recurrence (p = 0.02) and distant metastasis (p = 0.001). The knockout of the DAP1 gene in MCF-7 cell lines resulted in a significant decrease in the mRNA expression of P-21 and DELE compared with controls, p = 0.04). However, the knockout of DAP1 had no effect on the expression of caspase 8 and 9. CONCLUSIONS: This study demonstrates an inverse association between DAP1 mRNA levels and tumour stage and clinical outcome in breast cancer. This may be suggestive of a relationship between oncogenesis and the autophagy pathway meriting further investigation. These results also indicate that the pro-apoptotic function seems to be estrogen-dependent but independent of caspase 8 and 9. The DAP1 pro-apoptotic pathway may involve P-21 and DELE proteins. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-04-07.
NI-28 * ANALYSIS OF BEVACIZUMAB RESPONSE TO DISTINGUISH BETWEEN TUMOR RECURRENCE AND CEREBRAL RADIATION NECROSIS
Authors: K. Fujimoto, Y. Arakawa, D. Murata, N. Fukui, T. Kunieda, Y. Takagi, S. Miyamoto
Journal: Neuro-Oncology (2014)

OBJECTIVE: Recurrent malignant gliomas are the disease stage difficult to control progressive tumor (PT). Most of them has a treatment history of radiotherapy and there are more than a few lesion with a component of cerebral radiation necrosis (RN) (Fujimoto, 2013). Bevacizumab (BEV) is a possible therapeutic option for RN as well as recurrent malignant glioma. In this study, we investigate the components of PT and RN in patients with recurrent malignant glioma by image analysis before and after administration of BEV. PATIENTS AND METHODS: Six patients with malignant glioma had been treated with radiation therapy. Their disease progression were identified, which contained a component of RN detected by MRI and 11C-methionine-PET (met-PET). All patients received BEV 5mg/kg every 2 week. We analyzed the lesion with MRI and met-PET. RESULTS: The enhanced lesions with high uptake (SUV > 1.8) in met-PET got decreased enhancement and stable apparent diffusion coefficient (ADC) value after BEV treatment, in which tumor recurrence appeared to occur. The enhanced lesions with low uptake (SUV < 1.8) in met-PET decreased both their enhancement and ADC value, in which no tumor recurrence was identified. CONCLUSION: It is difficult to distinguish between PT and RN because of both lesions have similar findings on MRI. Our findings suggests that the enhanced lesion decreasing ADC value followed by BEV mainly consists of RN. The changes of ADC value by BEV may be concerned with the declining neovascularity and interstitial edema.
Mapping the goal space: Personality integration and higher-order goals
Authors: Jacob B. Hirsh
Journal: Behavioral and Brain Sciences (2014)

Abstract By situating goals at the heart of human cognitive function, Huang &amp; Bargh (H&amp;B) provide a useful platform for understanding the process of personality integration as the gradual mapping of implicit motives into a coherently organized self-system. This integrative process is a critical feature of human development that must be accounted for by any complete goal theory.
Vasovagal Syncope after Infusion of a Vasodilator in a Heart-Transplant Recipient
Authors: Urs Scherrer, Susanne Vissing, Barbara J. Morgan, Peter Hanson, Ronald G. Victor
Journal: New England Journal of Medicine (1990)

HYPOTENSIVE states are well known to activate the sympathetic nervous system, leading to reflex vasoconstriction and tachycardia.1 Hypovolemic hypotension, however, can be accompanied by paradoxical withdrawal of sympathetic drive, leading to vasodilation and bradycardia — responses that, in turn, exacerbate the decrease in blood pressure.2 3 4 5 In humans, hypotension with an inappropriately normal or frankly decreased heart rate has been observed during hemorrhagic shock,6 after the infusion of vasodilators,7 and most recently, in response to the infusion of isoproterenol during the upright-tilt test, which is used to provoke syncope.8 , 9 The current belief is that this type of vasodepressor reaction is a . . .
Abstract 1582: Identification of miRNAs that regulate breast cancer stem cells and spontaneous metastases in orthotopic mouse models
Authors: Huiping Liu, Jessica Bockhorn, Rachel Dalton, Olufunmilayo F. Olopade, Michael F. Clarke, Geoffrey L. Greene
Journal: Cancer Research (2011)

Abstract To examine the role of microRNAs (miRNAs) in breast cancer progression, we profiled miRNA expression in both clinical breast tumors and human-in-mouse breast tumor models, where breast cancer stem cells (BCSCs) contribute to spontaneous metastasis. CD44+ cells from both primary tumors and lung metastases were highly enriched for tumor initiating cells. Based on the miRNA profile analyses, we identified a limited number of miRNAs that are differentially expressed in metastatic triple-negative breast tumors and that regulate BCSCs and tumor invasion in vitro. To facilitate miRNA functional studies in vivo, we also developed tumor imaging approaches by transducing BCSCs with optical reporter fusion genes (Luc2-eGFP or -tdTomato), which enabled both bioluminescence imaging (BLI) and FACS-based analysis and sorting. With non-invasive BLI approaches, as few as 10 cells of stably labeled BCSCs can be tracked in vivo. When optical reporters are expressed along with miRNA precursors or inhibitors, the effects of introduced miRNA candidates can be evaluated by selective imaging of the transduced tumor cells, thereby eliminating the noise of un-transduced cells. Using this model system and imaging technology, we have screened and identified miRNAs that regulate BCSCs (e.g. miR-200 family) and metastatic CSCs (MCSCs). Our metastatic cancer models, combined with non-invasive imaging techniques, comprise an integrated approach that could be applied to dissect the molecular mechanisms underlying the dissemination of MCSCs, to explore therapeutic strategies targeting metastasis in general, or to evaluate individual patient tumor cells and predict response to therapy. Supported in part by the NIH T90, DOD BC087695 and Chicago Fellows Program at The University of Chicago (H.L.), University of Chicago Cancer Research Center Pilot Research Fund, UCMC/Northshore Collaborative Research Award and Ludwig Fund (G.L.G and H.L). NIH R01 and Breast Cancer Research Foundation (M.F.C. and H.L.). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1582. doi:10.1158/1538-7445.AM2011-1582
Abstract 2434: A genetically engineered mouse for imaging of apoptosis in a tissue specific manner
Authors: Stefanie Galbán, Yong Hyun Jeon, Lisa M. Sharkey, Benjamin A. Hoff, Craig J. Galban, Brian D. Ross, Alnawaz Rehemtulla
Journal: Cancer Research (2012)

Abstract The importance of the apoptotic machinery is exemplified in a number of disease processes. For example, inhibition of apoptosis can result in a number of cancers, autoimmune diseases, inflammatory diseases, and viral infections. Cancer is characterized by dysregulated cell proliferation and altered cell death, which constitutes a common basis for neoplastic evolution. The most implicit and clinically attractive anticancer strategies, therefore, consist of eliminating tumor cells by preventing their expansion and ultimately inducing apoptotic cell death. We have developed a transgenic mouse model wherein Caspase 3 mediated cell death can be imaged in real time and non-invasively utilizing a luciferase based biosensor. Upon Cre-mediated recombination, transgene expression containing the Caspase 3 biosensor is achieved in a cell or tissue specific manner. Here we show that expression of the Caspase 3 biosensor can be achieved in several tissues. In addition, we demonstrate in mouse models of cancer, that the ability to dynamically and sensitively image the activation of the Caspase 3 provides an opportunity to understand the dynamics of cell death in response to specific drugs or combination therapies. We also provide results demonstrating the utility of the technology in evaluating the efficacy of cancer therapeutics in cancer stem cells, a population that is rare and transient. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2434. doi:1538-7445.AM2012-2434
Abstract P6-05-09: Unravelling the global effect of estrogen on breast cancer cell proteome using quantitative proteomics.
Authors: MP Pavlou, AP Drabovich, A Dimitromanolakis, EP Diamandis
Journal: Cancer Research (2012)

Abstract Estrogens exert their function through genomic and non-genomic pathways mediated mainly by estrogen receptors. Estrogen signalling is highly complex and once activated initiates cancer cell proliferation and survival, playing a pivotal role in breast cancer development and progression. The identification of estrogen regulated genes is the first step towards elucidating the mechanisms of estrogen function. Although numerous studies have investigated the effect of estradiol at the mRNA level, assessment of global changes at the protein level has been limited mainly due to technological limitations. Here, we present the most extensive proteomic study in the quest of proteins whose expression is regulated or associated with estradiol action. To facilitate accurate quantification of proteins, we first developed and optimized a proteomic protocol for cell lysis and sample preparation, based on a mass spectrometry-compatible detergent. Following our protocol coupled to stable isotope labelling with amino acids in cell culture (SILAC) of MCF-7 breast cancer cells, we quantified approximately 4,000 proteins and identified 153 proteins differentially expressed upon estradiol stimulation. Notably, known estrogen regulated proteins such as trefoil 1(TFF1) and progesterone receptor (PGR) showed a four- and three-fold increase respectively, at 48 hours after estradiol stimulation. Forty eight of 153 differentially expressed proteins have been found to contain estrogen receptor elements (EREs) indicating direct regulation by estradiol. Protein-protein network analysis (STRING) revealed an extensive protein network related to cell proliferation. Differential expression of proteins was verified in three estrogen receptor positive breast cancer cell lines (MCF-7, HCC-1428, BT-483) using a targeted mass spectrometry-based quantitative approach; selected reaction monitoring (SRM). A multiplex SRM assay was developed for the simultaneous quantification of 56 proteins. The same assay was utilized to study the kinetics of these proteins in time and in presence of inhibitors of estrogen receptor facilitating the distinction between direct and indirect protein targets. To our knowledge, such an extensive network of estrogen-regulated genes has never been previously studied at the protein level. Interestingly, numerous differentially expressed proteins identified in the present study have not been connected to estrogen signalling or breast cancer before. The role of these proteins in breast carcinogenesis and their potential as therapeutic targets warrants further investigation. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-05-09.
Case 2-1990
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, S.D. Salman, F. Graeme-Cook
Journal: New England Journal of Medicine (1990)

Presentation of CaseA 63-year-old woman was admitted to the hospital because of chronic bilateral maxillary sinusitis and hilar and mediastinal lymphadenopathy.The patient was in a stable state of health until five months earlier, when x-ray films of the paranasal sinuses, obtained in evaluation of bilateral iritis, showed complete opacification of both maxillary sinuses (Fig. 1), compatible with marked membrane thickening; the ethmoid, frontal, and sphenoid sinuses appeared normal, and no bony abnormalities were seen. Two months before entry an x-ray film of the chest revealed that the heart was at the upper limit of normal in size, and . . .
Castleman Disease in the Anterior Neck: The Role of Ga-67 Scintigraphy
Authors: TOSHIBUMI KINOSHITA, KIYOSHI ISHII, YOUKO MORI, HIROSHI NAGANUMA
Journal: Clinical Nuclear Medicine (1996)

A case of Castleman disease in the anterior cervical region is presented. Ga-67 scintigraphy revealed moderate uptake in the thyroid region. Thyroid scintigraphy demonstrated the presence of an extrinsic thyroid tumor. Contrast-enhanced CT showed dense homogeneous enhancement within, the tumor. Radionuclide tracer accumulation on gallium scintigraphy as well as dense contrast enhancement on CT scan may be characteristic of Castleman disease. Castleman disease should be considered in the differential diagnosis when increased tracer activity is noted in an anterior cervical extrathyroid tumor on Ga-67 scintigraphy.
PWE-259 The efficacy of methotrexate in Crohn's disease: a clinical perspective
Authors: T T Gordon-Walker, M W Stahl, M Groome, J Todd, N Reynolds, C Mowat
Journal: Gut (2012)

<h3>Introduction</h3> Methotrexate (MTX) has been shown in clinical trials to be effective in the induction and maintenance of remission in Crohn9s Disease (CD). It is predominantly used in patients intolerant of, or whose disease is refractory to, thiopurine treatment. It was our aim to examine, in a clinical setting, the efficacy and side-effect profile of MTX in patients with CD. <h3>Methods</h3> A retrospective audit was performed by casenote review of all patients with CD attending the clinical investigations unit at Ninewells Hospital to commence parenteral MTX during the period 1 January 2007 to 31 December 2010. A total of 53 patients were identified, for whom casenotes were available in 52 (26 male/26 female). Intramuscular MTX treatment was initiated at a dose of 25 mg once weekly for 16 weeks, followed by oral MTX at a dose of 15 mg once weekly. Clinical response by physician9s global assessment was recorded at 3, 6 and 12 months. Clinical response was defined as complete response (absence of IBD symptoms or complete healing of fistulae); partial response (symptomatic improvement but ongoing symptoms); or no response (no improvement or deterioration from baseline). Relapse was defined as deterioration in symptoms necessitating additional medical or surgical intervention. <h3>Results</h3> Median age of starting MTX was 32 (range 15–73). 51 of 52 patients had previously received thiopurine treatment. 12-month follow-up data were available for 48 patients. 34 patients were taking steroids at the time of initiating MTX. At 12 months, complete response was reported in 8 patients (17%), partial response in 6 patients (13%), no response in 21 patients (44%) and drug withdrawal due to side effects in 13 patients (27%). Relapse was reported in 17 patients (35%). 10 patients (21%) required additional medical therapy (steroids or biological therapy). Surgical intervention was required in seven patients (15%). Steroid withdrawal at 1-year, without recourse to biological or surgical therapy, was reported in only 11 of 34 patients (32%). MTX-associated side effects were reported in 25 patients (48%). Reported side effects included: LFT abnormalities (9), nausea (8), lymphopenia (5), lethargy (3) and mouth ulceration (1). Monitoring of FBC/LFTs was performed at 97% of scheduled weekly intervals for patients receiving parenteral MTX and at 74% of scheduled monthly intervals for patients on oral MTX. <h3>Conclusion</h3> In this cohort, the clinical effectiveness of MTX in the induction and maintenance of remission of CD was limited. Only 29% of patients had either a complete or partial response to therapy at 1-year. The clinical effectiveness of MTX was limited by side-effects in 27%. On the basis of these results we should re-consider the position of MTX in the management of CD. <h3>Competing interests</h3> None declared.
ATRIAL FIBRILLATION “BURDEN” RATHER THAN A SINGLE ARRHYTHMIA RECURRENCE IDENTIFIES RISK OF ADVERSE CARDIOVASCULAR EVENTS ON ANTIARRHYTHMIC DRUGS: FURTHER INSIGHTS FROM THE AFFIRM TRIAL
Authors: Sanjeev Saksena, April Slee, Marwan Saad, Rangadham Nagarakanti
Journal: Journal of the American College of Cardiology (2015)